On the stock market since 2014, it operates in the world of health and science. It has 644 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $379.8M a year. A small number, but proof the product has real buyers.
There is $177.2M in the vault; even if every debt were paid off, $151.0M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $21.4M against $379.8M in annual sales.
This stock swings about 2.4 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, CDNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CDNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (58/100) says the stock isn’t cheap.